We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
Bibliographical noteFunding Information:
This study was supported by the Medicine and Bio Project for ‘Development of New Medicine and Medical Material’ (Project No. 70007613, entitled ‘Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus’) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.
© 2015 Elsevier Ireland Ltd.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism